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Abstract
Intravenous immunoglobulin G (IVIg) is widely used against a range of clinical symptoms. For its use in immune modulating
therapies such as treatment of immune thrombocytopenic purpura high doses of IVIg are required. It has been suggested
that only a fraction of IVIg causes this anti immune modulating effect. Recent studies indicated that this fraction is the
Fc-sialylated IgG fraction. The aim of our study was to determine the efficacy of IVIg enriched for sialylated IgG (IVIg-SA (+))
in a murine model of passive immune thrombocytopenia (PIT). We enriched IVIg for sialylated IgG by Sambucus nigra
agglutinin (SNA) lectin fractionation and determined the degree of sialylation. Analysis of IVIg-SA (+) using a lectin-based
ELISA revealed that we enriched predominantly for Fab-sialylated IgG, whereas we did not find an increase in Fc-sialylated
IgG. Mass spectrometric analysis confirmed that Fc sialylation did not change after SNA lectin fractionation. The efficacy of
sialylated IgG was measured by administering IVIg or IVIg-SA (+) 24 hours prior to an injection of a rat anti-mouse platelet
mAb. We found an 85% decrease in platelet count after injection of an anti-platelet mAb, which was reduced to a 70%
decrease by injecting IVIg (p,0.01). In contrast, IVIg-SA (+) had no effect on the platelet count. Serum levels of IVIg and
IVIg-SA (+) were similar, ruling out enhanced IgG clearance as a possible explanation. Our results indicate that SNA lectin
fractionation is not a suitable method to enrich IVIg for Fc-sialylated IgG. The use of IVIg enriched for Fab-sialylated IgG
abolishes the efficacy of IVIg in the murine PIT model.
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Introduction
Intravenous immunoglobulin G (IVIg) is a therapeutic immuno-
globulin G preparation derived from pooled plasma of at least 1000
healthy blood donors. It was initially developed as a replacement
agent for treating primary and secondary antibody deficiencies.
However, since nearly three decades immune modulating therapy
of acute and chronic autoimmune diseases became a second major
clinical indication for IVIg therapy [1–4]. Many patients with acute
and chronic autoimmune diseases benefit from IVIg treatment,
althoughitsuseisnotinallcaseseffective[5].Fromclinicalstudiesit
is known that IVIg therapy is effective in the treatment of antibody-
dependent thrombocytopenia such as idiopathic thrombocytopenic
purpura (ITP) [6,7]. The main protective effect of IVIg in ITP
seemstobethe inhibition oftheFcc receptormediated phagocytosis
[8,9]. By injecting a high dose of IVIg Fcc receptor-bearing
phagocytic cells in the spleen are blocked and thereby prevent the
destruction of antibody opsonized platelets. F(ab’)2 fragments of
IVIg are not able to inhibit platelet clearance in a murine model of
thrombocytopenia [8].
Besides the Fcc receptor inhibition, another reason for the high
dose (1.0–2.0 g/kg) of IVIg required for therapeutic efficacy could
be that only a fraction of IVIg is causing the desired effects.
Identification of this fraction of IVIg would possibly allow the
development of a more effective IVIg preparation with a changed
composition designed for treating patients with autoimmune
diseases.
A recent study indicated that the Fc-sialylated IgG fraction is
the active immunomodulating entity in IVIg [10]. In this study,
the authors enriched IVIg for IgG containing sialic acid (IVIg-SA
(+)) using Sambucus nigra agglutinin (SNA) lectin fractionation. In a
murine K/N serum transfer model for rheumatoid arthritis they
found a 10-fold enhancement of the protective effect of IVIg-SA
(+). By using Fc fragments instead of intact IgG, they demonstrated
that sialylated Fc fragments likewise caused an enhanced
protection of the mice similar to IVIg-SA (+). They concluded
that the anti-inflammatory activity of IVIg is limited to Fc-
sialylated IgG molecules. Two years later the same group
confirmed the results by showing that a fully recombinant,
sialylated IgG1 Fc domain caused a comparable protective effect
[11]. The authors extended these findings by showing that SIGN-
R1 is involved in the binding of sialylated Fc fragments [12].
The abovementioned results of enhanced protection by using
sialylated Fc fragments are very convincing, although it is
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Fc-sialylated IgG. A recent study has demonstrated that the
binding of IVIg to SNA lectin is primarily mediated by Fab
glycosylation, and that for binding of the Fc part to the SNA lectin
column two sialic acid residues are required [13]. Analysis of the
glycosylation patterns of IVIg revealed that less than 1% of Fc
parts contain two sialic acid residues [13]. An earlier study showed
that a sialic acid residue attached to Fc part tends to be hidden
within the interface between the two CH2 domains which makes
this sialic acid residue inaccessible for SNA lectin binding [14].
They demonstrated that under native conditions SNA lectin
binding is restricted to the sialic acid residues attached to the Fab
part. SNA lectin bound to the Fc part only under reducing
conditions (which opens up the interface between the CH2
domains) [14].
The aim of our study was to extend these findings to another
case where immune modulating effects of IVIg are most likely Fc-
mediated. Therefore, we wanted to investigate whether IVIg
enriched for sialylated IgG using SNA lectin fractionation
enhances the efficacy (immune modulating effect) of IVIg in a
murine model of passively induced immune thrombocytopenia
(PIT). Our results indicate that SNA lectin fractionation is not a
suitable method to enrich IVIg for Fc-sialylated IgG. Moreover,
use of IVIg enriched for Fab-sialylated IgG resulted in a decrease
rather than an increase of the efficacy of IVIg in the used murine
model of passive immune thrombocytopenia.
Results
SNA-lectin affinity-enriched IVIg
IVIg was enriched or depleted for sialylated IgG by using SNA
lectinfractionation asdescribed byKanekoet al. [10].Thistwo-step
elution resulted in two enriched fractions, with yields of ca. 4.5%
and 1.5% for fraction 1 and 2, respectively. The experiments
described from here on were carried out using fraction 1 only.
However, additional experiments were also carried out using
fraction 2, as described in Text S1. Similar results were obtained for
both fractions. To measure the degree of sialylation under native
(non-reduced) conditions we used a SNA lectin inhibition ELISA.
As shown in Figure 1A IVIg-SA (+) inhibited the binding of
biotinylated SNA lectin to the IgG coat more efficiently than IVIg,
whereas IVIg-SA (2) resulted in a less efficient inhibition. As shown
in Table 1, IVIg-SA (+) was approximately 13-fold more potent to
inhibit SNA lectin binding to IgG than IVIg, whereas the inhibition
by IVIg-SA (2) was minimal and could not be quantified.
Next, we determined the site of sialylation by measuring the
degree of Fab- and Fc-sialylation. Fab fragments derived from
IVIg-SA (+) were approximately seven-fold more potent to inhibit
SNA lectin binding to IgG than Fab fragments derived from IVIg,
whereas no inhibition of SNA lectin binding was visible using Fab
fragments derived from IVIg-SA (2) (Figure 1B and Table 1).
Importantly, none of the Fc fragments were able to inhibit SNA
lectin binding to IgG.
Figure 1. Measurement of the degree of sialylation by SNA lectin inhibition ELISA. % SNA lectin binding after pre-incubation A) with IVIg,
IVIg-SA (+) or IVIg-SA (2) B) with Fab and Fc fragments derived from IVIg, IVIg-SA (+) or IVIg-SA (2) C) with Fab or protK digested Fab fragments
derived from IVIg, IVIg-SA (+) or IVIg-SA (2) D) with Fc or protK digested Fc fragments derived from IVIg, IVIg-SA (+) or IVIg-SA (2). Data represents
mean 6 SEM, n=3.
doi:10.1371/journal.pone.0021246.g001
Sialylated IgG in IVIG
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observed an inhibition of the SNA lectin binding to IgG
indicating that under denatured conditions the sialic acid residues
attached to the Fc part are available for SNA lectin binding. The
inhibition of the SNA lectin binding to IgG was approximately
2.5 fold less potent than IVIg. Moreover, the degree of inhibition
was identical for all Fc fragments (Table 1). Similarly, Western
blot analysis showed that under reduced conditions SNA lectin
binding to the Fc fragments was identical (data not shown)
confirming the ELISA results and results of earlier studies
[13,14].
To confirm the ELISA results, the degree of Fc sialylation of
IVIg and IVIg-SA (+) was determined by mass spectrometric
analysis of glycopeptides (Figure 2). Notably, the specific peptide
moiety present on the registered glycans ensures that this method
only registers IgG1 Fc glycosylation, without any interference from
Fab glycosylation [13,15]. The glycosylation profiles obtained for
the two samples were very similar and showed no enrichment of
sialylated Fc glycoforms in IVIg-SA (+). Signal intensities were
quantitatively compared, and on the basis of the mass spectro-
metric signals very similar Fc glycopeptide sialylation levels of 12%
and 13% were determined for IVIg and IVIg-SA (+), respectively
(Table 2). Likewise, galactosylation (55% and 58%) and fucosyola-
tion (94% and 93%) levels were found to be very similar for IVIg
and IVIg-SA (+), respectively. A noticable difference was found for
the incidence of bisecting GlcNAc, which was 18% and 11% for
IVIg and IVIg-SA (+), respectively.
Table 1. Calculated potencies (depicted as mean with
corresponding CI*) of IVIg, IVIg-SA (+), their Fab fragments
and Fc protK digests to inhibit SNA lectin binding to IgG.
IVIg IVIg-SA(+) IVIg-SA(2)
IgG 1 13 (12.0–14.8) n.d.
Fab 0.49 (0.44–0.54)
a 3.6 (3.2–4.2)
a n.d.
7.0 (6.0–8.3)
b
Fc protK digest 0.39 (0.34–0.46)
a 0.39 (0.33–0.45)
a 0.41 (0.36–0.46)
a
0.87 (0.73–1.0)
c 0.95 (0.81–1.11)
c
a) relative to IVIg-IgG.
b) relative to IVIg-Fab.
c) relative to IVIg-Fc protK digest.
*CI confidence interval.
n.d. not determined.
doi:10.1371/journal.pone.0021246.t001
Figure 2. Mass spectrometric IgG1 Fc-glycosylation profiles of A) IVIg and B) IVIg-SA (+). A) IVIg and B) IVIg-SA (+) were subjected to
tryptic cleavage and analyzed by nanoLC-ESI-ion trap-mass spectrometry. Sum mass spectra of the elution range of the IgG1 Fc-glycopeptides are
shown. Glycopeptides were registered as proton adducts ([M+4H]
4+). All the displayed glycopeptides have 1 missed tryptic cleavage site and share
the peptide moiety T289KPREEQFNSTFR301 carrying a glycan at N297. *, contaminant or irrelevant peak.
doi:10.1371/journal.pone.0021246.g002
Sialylated IgG in IVIG
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Platelet count. The biological effect of sialylated IgG was
tested using a well established murine model of passive-immune
thrombocytopenia as described earlier [8] (Figure 3).
As shown in Figure 4, mice receiving mAb (saline/mAb
group) displayed severe thrombocytopenia. The platelet count
dropped to a level of around 15% (154620*10
9 cells/L)
compared to the control mice 923661*10
9 cells/L (saline/saline
group). Furthermore, administration of solely IVIg did not by
itself cause any changes in platelet count (IVIg/saline group,
905627*10
9 cells/L).
Pre-treatment with a high dose (1.5 g/kg) IVIg had a protective
effect (Figure 5A). The mice that received IVIg or IVIg-SA (2)
had a significantly higher platelet count (350639 and 292636*10
9
cells/L, respectively) compared to the mice receiving no IVIg pre-
treatment (P,0.01). Thus, a single dose of IVIg or IVIg-SA (2)
resulted in an increase of platelets, reaching a platelet count of
about 35% of baseline value. Our results confirm the results of
Crow et al. [8] but are in contrast with the results of Teeling et al.
who found that the platelet clearance after the induction of
thrombocytopenia was only reduced using an IVIg product which
underwent a process of ‘ageing’ [16].
In contrast to IVIg and IVIg-SA (2), no increase in platelet
count was observed after pre-treatment with IVIg-SA (+). The
platelet count dropped to the same level (154670*10
9 cells/L) as
Table 2. IgG1 Fc-glycosylation features of IVIg before and
after SA-enrichment.
Incidence (%)
Glycosylation feature
Registered
signal (m/z) IVIg IVIg-SA (+)
H3N4 743.4 1 1
H3N4F1 779.9 16 15
H4N4 783.9 2 2
H4N4F1 820.4 31 36
H5N4 824.6 2 2
H3N5F1 830.7 6 3
H5N4F1 860.9 18 20
H4N5F1 871.4 10 7
H4N4F1S1 893.1 2 2
H5N4S1 897.2 1 1
H5N5F1 911.7 2 2
H5N4F1S1 933.7 10 10
Galactosylation - 55 58
Sialylation - 12 13
Incidence of bisecting GlcNAc - 18 11
Fucosylation - 94 93
Glycopeptides were registered by nanoLC-ESI-ion trap-mass spectrometry (see
Figure 2). Peak heights of glycopeptide signals (proton adducts [M+4H]
4+) were
integrated and normalized to the total peak heights of glycopeptide signals.
The average of two measurements is given.
doi:10.1371/journal.pone.0021246.t002
Figure 3. Schematic representation of the passive-immune
thrombocytopenia mouse model.
doi:10.1371/journal.pone.0021246.g003
Figure 4. Measured platelet count at t=16 hours of the control
groups. Results are depicted as mean with error bars representing
standard error of mean (SEM), (n=10–12 mice per group). At t=224 h,
platelet counts were 913652*10
9,9 1 5 628*10
9, and 867638*10
9 cells/L,
respectively.
doi:10.1371/journal.pone.0021246.g004
Figure 5. Measured platelet count at t=16 hours after IVIg
pre-treatment. Pre-treatment with A) a high dose (1.5 g/kg) of IVIg,
IVIg-SA (2), IVIg-SA (+), or saline. B) a low dose (0.3 g/kg) of IVIg, IVIg-
SA (2) IVIg-SA (+), or saline. Results are depicted as mean with error
bars representing standard error of mean (SEM), (n=10–12 mice per
group). * P,0.01.
doi:10.1371/journal.pone.0021246.g005
Sialylated IgG in IVIG
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lower dose (0.3 g/kg) had no effect (Figure 5B). In separate
experiments, also IVIg-SA (+) from fraction 2 was tested and
compared to IVIg-SA (+) from fraction 1. Neither of these
materials resulted in an increase in platelet count (Figure S1).
Human IgG concentration and subclass distri-
butions. To rule out the possibility that the lower efficacy of
IVIg-SA (+) was caused by a lower human IgG concentration in
the blood circulation of the mice, we determined the human IgG
concentration at t=16 hours using an anti-human IgG ELISA.
We observed no difference in human IgG concentrations in mice
after injecting a high dose (1.5 g/kg) of IVIg, IVIg-SA (2) or IVIg-
SA (+). The human IgG concentration at t=16 hours in the mice
which received IVIg, IVIg-SA (2), IVIg-SA (+) and IVIg without
mAb injection was respectively 2.260.1, 2.560.2, 2.660.2 and
2.360.2 mg/ml. There was no difference in human IgG
concentration after pre-treatment with a low dose (0.3 g/kg) of
IVIg (data not shown).
IgG subclass distributions of IVIg-SA (+) and IVIg were also
determined (Table S1). The IgG subclass distribution of IVIg-SA
(+) was not substantially different compared to IVIg, ruling out the
possibility that the lower efficacy of IVIg-SA (+) is caused by an
altered IgG subclass distribution.
Discussion
In the present study we used a murine model of thrombocy-
topenia to evaluate the effect of IVIg that differed in the amount of
sialylated IgG. We demonstrated that enrichment for sialylated
IgG did not enhance the efficacy of IVIg. By contrast, the
clearance of platelets could only be reduced by administrating
IVIg or IVIg-SA (2). IVIg-SA (+) had no effect on the platelet
count. This is in contrast to our hypothesis, which was based on
the findings of Kaneko et al. [10] and Anthony et al. [11].
We used the same method as described by Kaneko et al. [10],
and our ELISA analysis showed that we enriched for sialylated
IgG. However, we predominantly found enrichment in Fab-
sialylated IgG and not for Fc-sialylated IgG. Further analysis
revealed that SNA lectin binding to the Fc part only occurred
under non-native conditions (e.g. protK digestion or Western
blotting). From the literature it is known that monosialylation of
the Fc part is not sufficient for Fc binding to SNA lectin
[14,17,18]. Thus, our results indicate that IVIg contains
predominantly IgG with monosialylated Fc parts which are not
available for SNA lectin binding under native conditions and
thereby did not result in a substantial increase of Fc-sialylation in
IVIg. Nevertheless, it was suggested by Stadlmann et al. that
enrichment by SNA lectin chromatography is limited to
disialylated Fc parts [13,14], a fraction too small to detect but
arguably responsible for the immune modulating effects of IVIg as
found by Kaneko et al. Because we essentially enriched for sialic
acid similar to Kaneko et al., we propose that the lack of efficacy of
IVIg-SA (+) in our model points to a different mechanism of action
of IVIg in the PIT model compared to the murine K/N serum
transfer model for rheumatoid arthritis.
Various mechanisms of action of IVIg on different levels of the
immune system have been reported [19–23]. An important
immunomodulating mechanism of IVIg is the immune regula-
tion through the inhibitory Fcc-receptor (FccRIIb) on effector
macrophages [22,23]. In ITP, the main protective effect of IVIg
on platelet clearance is FccRIIb-mediated as IVIg had no effect
on the platelet count in FccRIIb
2/2 mice [24–26]. Our study
demonstrates that IVIg-SA (+) is less protective than IVIg on the
Fcc-receptor mediated platelet clearance. This lesser efficacy of
IVIg-SA (+) might be caused by a lower binding affinity to the
Fcc-receptors which has been reported previously [10,12].
Although FccRIIb is required for IVIg to be protective in the
arthritis model, the binding of IVIg-SA (+)t ot h eF c cRs was
reduced (10-fold lower affinity) indicating that other receptors
are also involved [10,12]. Further research using isolated Fc
parts showed that in mice the SIGN-R1 receptor and in humans
DC-SIGN, the human orthologue of SIGN-R1 is required,
suggesting a SIGN-R1/DC-SIGN mediated receptor signalling
of IVIg-SA (+) [12]. Besides the SIGN-R1/DC-SIGN mediated
receptor signalling Se ´ı ¨te ´ et al. [27] have recently demonstrated
that IVIg-SA (+) modulates B cell receptor signalling through the
binding to CD22 causing B cell apoptosis. Thus, our results
together with the literature suggest that enhanced efficacy by
treatment with IVIg-SA (+) instead of IVIg requires the
involvement of other receptors (e.g. SIGN-R1/DC-SIGN and
CD22 receptor) than FccRIIb. In ITP this is apparently not the
case and therefore IVIg-SA (+) has no enhanced efficacy
compared to IVIg.
The lack of increased efficacy of IVIg-SA (+) in our model could
be due to our failure to enrich for Fc-sialylated IgG, but this does
not explain why IVIg-SA (+) is actually less active than the starting
material. This suggests another reason for the lower efficacy of
IVIg-SA (+) in our model. One possibility is a selective depletion of
the effective antibodies. For instance, it has been suggested that
anti-idiotype antibodies to autoantibodies directed to glycoprotein
IIb/IIIa on platelets are involved in the protective effects of IVIg
[32]. Alternatively, an unknown target might be involved. Fab-
sialylated IgG antibodies might be less protective compared to
non-sialylated or Fc-sialylated IgG antibodies due to the presence
of Fab glycans. Fernandez-Cruz et al. reported that Ka ¨sermann
and his group found that the distribution of specific antibodies in
IVIg after SNA lectin fractionation differed [28] from unfraction-
ated IVIg, but in the scope of this study we did not further
analysed whether a selective depletion of effective antibodies
occurred. However, we did test if the enriched material has a
different IgG subclass distribution, which was not the case, ruling
out a selective depletion for one IgG subclass as a cause for the
reduced efficacy of IVIg-SA (+).
To exclude that the lower efficacy of IVIg-SA (+) was caused by
a lower human IgG concentration in the blood stream of the mice
due to a hypothetical shortened half-life of sialylated IgG we
measured the human IgG concentration in the blood samples. Our
results confirmed the results of Kaneko et al. [10] that the degree
of sialylation has no influence on the clearance.
We conclude that SNA lectin fractionation is not a suitable
method to enrich IVIg specific for Fc-sialylated IgG. By using this
method IVIg is predominantly enriched for Fab-sialylated IgG,
which does not enhance the efficacy of IVIg in our murine model
of thrombocytopenia. Having our SNA lectin fractionation results
and the literature [13,14,29] in mind, it is not clear whether the
described anti-inflammatory effect of IVIg in the murine K/N
serum transfer model for rheumatoid arthritis [10–12] can be
limited to Fc-sialylated IgG. As IVIg also contains Fab-sialylated
IgG [30] the anti-inflammatory activiy of IVIg-SA (+) might be
caused also by Fab-sialylated IgG.
Considering the results of this study, further research is required
to elucidate the role of IgG sialylation as well as IgG glycosylation
in more detail. It would be interesting to study a) the biological
effect of IgG containing no, one or two sialic acid residues at the
Fc part and IgG with or without a Fab-sialylated part using
different murine models (e.g. rheumatoid arthritis and thrombo-
cytopenia and b) the SIGN-R1/DC-SIGN binding of sialylated
IgG with and without removal of the Fab- and Fc-linked glycans.
Sialylated IgG in IVIG
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property but depends on the autoimmune disease.
Materials and Methods
Animals/Ethics statement
Virgin female Balb/c mice (6 weeks of age) were purchased
from Harlan (Harlan CPB, Zeist, Netherlands) and housed in the
animal facilities of the Dutch cancer institute. The institutional
ethics committee of the Dutch cancer institute approved the
animal experiments used in this study, permit number 2008.001.
Reagents
From Vector Laboratories (Burlingame, USA) we obtained both
the biotinylated and the agarose-coupled Sambucus nigra agglutinin
(SNA) lectin which recognizes a-2,6 linked sialic acid residues
(with a binding capacity of 1.5 mg fetuin/ml gel).
To induce thrombocytopenia, we used a rat anti-mouse platelet
mAb (MWReg30, IgG1) which targets the platelet-specific integrin
aIIbb3 (gpIIb/IIIa) (Pharmingen, San Diego, CA, USA).
Immunoglobulin preparations
Human c-globulin for intravenous (IVIg) use was obtained from
Sanquin (Nanogam, 5%; Amsterdam, The Netherlands). This
liquid IVIg product is prepared from pooled plasma from at least
1000 healthy donors by Cohn fractionation followed by a low-dose
pepsin treatment at pH 4.0, 15 nm filtration, solvent-detergent
treatment and formulated as 5% (w/v) solution in 5% glucose
solution pH 4.5. It was stored at 4uC.
Preparation of sialic acid enriched or depleted IVIg by
SNA lectin fractionation
To increase the proportion of sialylated IgG (SA-IgG) in IVIg
SNA lectin fractionation (also referred as SNA lectin affinity
chromatography) was used as described by Kaneko and co-
workers [10]. Briefly, IVIg was dialyzed against Tris-buffered
saline (TBS) containing 0.1 mM CaCl2 and 200 mg dialyzed IVIg
was applied to a 10 ml agarose-bound SNA lectin column. The
flow-through fraction (SA-IgG depleted IVIg=IVIg-SA (2)) was
collected by washing the column with 20 ml TBS containing
0.1 mM CaCl2. Next, the sialic acid enriched fraction of IVIg was
eluted in 2 steps using 20 ml of 0.5 M lactose in TBS (fraction 1,
yield 4.5% followed by 20 ml of 0.5 M lactose in 0.2 M acetic acid
(fraction 2, yield 1.5%). All fractions were dialyzed against water
and concentrated to a protein concentration of 50 mg/ml using a
Centrifugal filter device (cut off 10 kDa, Amicon, Millipore,
Billerica, MA, USA). After a sterile filtration, glucose was added to
obtain the same formulation as IVIg with a final pH of 4.5.
Papain digestion of IVIg
To determine the site of sialylation, Fab and Fc fragments were
prepared by treating IVIg, IVIg-SA (+) and IVIg-SA (2) with
DTT pre-activated papain (Sigma-Aldrich, St. Louis, MO, USA)
at an enzyme : antibody ratio of 1:400 in phosphate buffered saline
(PBS) pH 7.4 with 3 mM EDTA at 37uC for 3 hours. The
reaction was stopped by adding fresh iodoacetamide (Sigma-
Aldrich, St. Louis, MO, USA) to a final concentration of 83 mM.
The digested fraction was separated from the undigested fraction
by size exclusion chromatography using a Hiload 16/60 Super-
dex200 column (60 cm, 124 ml, GE Healthcare, Uppsala,
Sweden) connected to a HPLC system (GE Healthcare). The
Fab fragments were separated from the Fc fragments by charge
using a MonoQ column (GE Healthcare). To further purify the Fc
fragments protein G affinity chromatography was used. Briefly, we
respectively loaded 0.8 mg, 0.7 mg or 1 mg of Fc fragments
derived from IVIg-SA (+), IVIg-SA (2) or IVIg on a protein G 4
Fast Flow column with a packed column volume of 250 ml (GE
Healthcare). After washing with 10 column volumes PBS the
bound Fc fragments were eluted with 6 column volumes 100 mM
Glycine pH 2.8 followed by an immediate neutralization with 2 M
K2HPO4. After overnight dialysis against PBS at 4uC and the
addition of sodium azide (NaN3) with a final concentration of
0.05% the fragments were stored at 4uC.
Proteinase K digestion of Fc fragments
To determine the degree of Fc sialylation, Fc fragments derived
from IVIg, IVIg-SA (+) or IVIg-SA (2) were digested with protK
(proteinase K, Sigma-Aldrich, St. Louis, MO, USA). The Fc
fragments were overnight dialyzed against PBS at 4uC, followed by
incubation with protK (ratio 0.6 U/mg protein, overnight, at
50uC). The protK was inactivated by incubating the mix at 80uC
for 3 minutes. After the addition of sodium azide (NaN3) with a
final concentration of 0.05% the digested Fc fragments were stored
at 4uC.
Determination of the degree of sialylation
To determine the degree of IgG sialylation the following
methods were used:
Lectin inhibition ELISA. To measure the sialic acid content
under native conditions and in protK digests, we used an enzyme-
linked immunosorbent assay (ELISA). Biotinylated SNA lectin
diluted to 0.5 mg/ml in phosphate buffered saline (PBS) containing
0.1% Tween20 was pre-incubated with the inhibitors (IVIg, IVIg-
SA (+), IVIg-SA (2), Fab or Fc fragments) for 1 hour at RT. After
adding the mix to an IVIg coated microtiter plate (Maxisorp;
Nunc, Roskilde, Denmark), we incubated the plate for 1 hour at
RT. Subsequently, the plates were washed and streptavidin-HRP
(Amersham, Uppsala, Sweden) diluted 1:4000 in PBS/0.1%
Tween20 was added. After 1 hour incubation at RT the plates
were washed and 100 ml/well TMB substrate buffer (Interchim,
Montluc ¸on Cedex, France) diluted with an equal volume of
distilled water was added. The reaction was stopped with 2 M
H2SO4 after 5 minutes and the absorbance was measured at
450 nm with a Titertek multiscan.
Mass spectrometric analysis of IgG1 Fc glycosy-
lation. For mass spectrometric Fc-glycosylation analysis IVIg
samples were subjected to trypsin treatment, and resulting
glycopeptides were analyzed by nano-LC-ion trap-MS as
described elsewhere [15]. In accordance with an earlier report
IgG1 Fc-glycopeptides exhibited a missed tryptic cleavage site
resulting in the peptide moiety T289KPREEQFNSTFR301 carrying
a glycan at N297 [17]. Glycopeptides were assigned in terms of
monosaccharide composition, i.e. hexose (H), N-acetylhexosamine
(N), deoxyhexose (F), and N-acetylneuraminic acid (S). Peak heights
of glycopeptide signals (proton adducts [M+4 protons]
4+) were
integrated and normalized to the total peak heights of glycopeptide
signals. Glycosylation features were calculated as follows: galacto-
sylation=H5N4+H5N4F1+H5N4S1+H5N5F1+H5N4F1S1+0.5 *
(H4N4+H4N4F1+H4N5F1+H4N4F1S1); sialylation=H4N4F1S1+
H5N4S1+H5N4F1S1; incidence of bisecting GlcNAc=H3N5F1+
H4N5F1+H5N5F1; fucosylation=H3N4F1+H4N4F1+H3N5F1+
H5N4F1+H4N5F1+H4N4F1S1+H5N5F1+H5N4F1S1.
IgG subclass distribution
IgG subclasses of IVIg, IVIg-SA (+), and IVIg-SA (2) were
determined using a nephelometric assay as described previously
[31].
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To induce passive-immune thrombocytopenia mice were
injected intraperitoneally with 2 mg of a rat-anti-mouse CD41
monoclonal antibody (MWReg30, BD Pharmingen, San Diego,
CA, USA) in 200 ml PBS containing 0.01% human serum
albumin. We measured the effect of sialic acid on IVIg by giving
IVIg, IVIg-SA (+), IVIg-SA (2) (1.5 or 0.3 g/kg) or saline
intraperitoneally 24 hours prior to injection of MWReg30. From
the retro-orbital plexus of anesthetized mice blood samples were
collected using tubes containing sodium citrate as anti-coagulant,
before IVIg or saline treatment (t=224), 5 minutes prior to
injection of MWReg30 (t=0) and 16 hours after injection of
MWReg30 (t=+16). Within 1 hour of blood collection, the blood
samples were diluted 1:5 in PBS and the number of platelets (PLT)
was counted by using the ADVIA 2120 haematology system
(Siemens Medical Solutions Diagnostics, Erlangen, Germany).
Detection of human IgG in mice
To measure the human IgG content in mice, we used an
enzyme linked immunosorbent assay (ELISA). A mouse anti-
human IgG (MH16-1, Sanquin, Amsterdam, Netherlands) coated
microtiter plate (Maxisorp, Nunc, Roskilde, DK) was incubated
with mouse serum diluted 1:100 in 0.9% NaCl/10 mM EDTA.
After 1 hour incubation at RT the plates were washed five times
with PBS/0.1% Tween20 and 100 ml/well of a polyclonal rabbit
anti-human IgG labelled with HRP (Sanquin, Amsterdam,
Netherlands) at a concentration of 0.5 mg/ml was added to the
wells and incubated 1 hour at RT. The binding was measured
adding 100 ml/well of a TMB substrate buffer (Interchim,
Montluc ¸on Cedex, France) diluted 1:2 with distilled water. The
human IgG concentration was determined by measuring the
absorbance at 450 nm using a Titertek multiscan.
Detection of MWReg30 in mice
Success of the injection of the rat-anti-mouse CD41 monoclonal
antibody (MWReg30) was assessed by measuring the HSA content
in mice, which was co-injected with the anti-CD41 antibody. To
detect HSA a radioimmunoassay (RIA) was set up. 200 ml sheep-
anti-HSA antibody (kindly provided by Sanquin Diagnostics,
Amsterdam, Netherlands) was coupled to 200 mg Sepharose
according to the manufacturer’s instructions (GE Healthcare,
Uppsala, Sweden) followed by a dilution in PBS to a concentration
of 2 mg/ml. For testing, 50 ml mouse serum was incubated with
250 ml of Sepharose. After rotating overnight at RT, the
Sepharose was washed five times with PBS/0.1% Tween and
incubated with
125I (GE Healthcare, Uppsala, Sweden) radioactive
labelled double depleted sheep-anti-HSA antibody (depleted for
sheep anti-human IgG antibodies and sheep anti-mouse serum).
After overnight incubation at RT the Sepharose mix was washed
four times with PBS/0.1% Tween and the radioactivity was
measured using a Wallac counter. The sera of saline-injected mice
were used as negative control.
Analysis of data
Degree of sialylation. To compare the degree of sialylation
of IVIg, IVIg-SA (+), IVIg-SA (2) and their Fab fragments their
relative potencies in the SNA lectin inhibition ELISA were
calculated by parallel line analysis [29]. A value above 1 for a
fraction indicates that this fraction is more potent than IVIg, thus
is enriched for sialic acid.
PIT mouse model. To analyze differences in platelet count a
Student t-test was performed. Two-sided tests with P-values less
than 0.05 were considered to indicate a statistically significant
difference.
Mice were excluded if results of the RIA (see above) was below
the cut-off value of the test, indicating an incorrect intraperito-
neally injection of the MWReg30 antibody. As cut-off value, the
mean binding of the negative control group +2*standard deviation
was used. We excluded 6 from the 120 mice from analysis. These
mice were randomly distributed along the 10 groups.
Supporting Information
Figure S1 Measured platelet count at t=16 hours after
high dose IVIg pre-treatment. Pre-treatment with a high dose
(1.5 g/kg) of IVIg, IVIg-SA (+) 1, IVIg-SA (+) 2, or Saline as
described in the text below. Results are depicted as mean with
error bars representing standard error of mean (SEM), (n=9).
** P,0.01, * P,0.05.
(PDF)
Table S1 IgG subclass distribution in IVIg fractions
(in %).
(PDF)
Text S1 Platelet counts after pre-treatment with fractions
1a n d2 .
(PDF)
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